TOX

Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy

Positive interim results prompt request for meeting with FDA SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced today that interim results ofits phase II/III trial comparing CPOP-R, in which pixantrone issubstituted for doxorubicin in standard CHOP-R first-line treatmentof patients with aggressive non-Hodgkin's lymphoma (NHL), resultedin essentially al...

Protox Announces Positive Clinical Data from Prostate Cancer Study

VANCOUVER, British Columbia, July 10, 2007 /CNW/ - ProtoxTherapeutics Inc. (TSX-V:PRX) today announced positivetop-line results from its Phase 1 clinical trial evaluating PRX302 in patients with localized, recurrent prostate cancerfollowing radiation failure. The trial results indicate thatPRX302 is safe and well tolerated and shows promising signsof therapeutic activity following a s...

DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC

MIAMI, FL -- (MARKET WIRE) -- July 06, 2007 -- DOR BioPharma,Inc. (OTCBB: <a target="_blank" href='http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB"%3EDORB'>http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB">DORB )("DOR" or the "Company") announced today that the European PatentOffice has granted a paten...

DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC

MIAMI--(MARKET WIRE) -- July 02, 2007 -- DOR BioPharma, Inc.(OTCBB: DORB) ("DOR" or the "Company") announced today that thefirst results from testing of a multivalent form of its botulinumtoxin vaccine, BT-VACC™, have been published in the journalInfection and Immunity (Ravichandran et al., 2007, Infection andImmunity, v. 75, p. 3043 ). These results are the first thatdescribe the...

RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments

IRVING, Texas--(BUSINESS WIRE)--Jun 29, 2007 - ReataPharmaceuticals, Inc. today announced the presentation of newpreclinical data showing their lead anti-cancer agent, theSynthetic Triterpenoid RTA 402, is effective at protecting againstcommon toxicities caused by traditional cancer treatments. Thisdata was presented at the annual meeting of the MultinationalAssociation of Supportive Care i...

Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone

Interim results in a randomized phase II/III clinical trialanticipated later this year SEATTLE, June 26, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced the publication of preclinicalstudies, which demonstrate that treatment with pixantrone (BBR2778) resulted in minimal or no significant cardiotoxicity, whiledoxorubicin and mitoxantrone induced significant cardiac da...

Vastox Awarded £400,000 Grant to Support R&D at Carbohydrate Chemistry Facility

OXFORD, England, 20 June 2007 - VASTox plc (AIM: VOX), a leadingUK biotechnology company, announces that it has been awarded agrant of £400,000 by the Welsh Development Agency(”WDA”) under the SMARTCymru scheme. The grant,which runs for 12 months, will support the research and developmentwork undertaken at VASTox’s Aberystwyth facility and providesrecognition of...

Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)

Preliminary Results of Largest Randomized, Placebo-controlled TrialEver Conducted in CTCL Presented at the American Society ofClinical Oncology CHICAGO, June 04, 2007 /PRNewswire/ -- Preliminary results ofthe largest randomized, placebo-controlled clinical trial everconducted in patients with cutaneous T-cell lymphoma (CTCL) showedthat ONTAK was more than twice as effective as placebo in...

First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A) Significantly Improves Idiopathic Detrusor Overactivity (IDO) in Patients With Symptoms of Overactive Bladder

Treatment Benefits Were Maintained for at Least 24 Weeks, Accordingto Report Published in The Journal of Urology LONDON, May 15, 2007 /PRNewswire/ -- Researchers from Guy'sHospital and King's College London School of Medicine haveannounced the results from the first randomized, double-blind,placebo-controlled study evaluating botulinum toxin type A (BTX-A,BOTOX(R)) as a treatment for idio...

Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients

KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data havedemonstrated that relapsing-remitting multiple sclerosis (RRMS)patients treated with COPAXONE(R) (glatiramer acetate injection)following brief immunosuppression with mitoxantrone experienced a90 percent reduction in magnetic resonance imaging (MRI)-monitoreddisease activity compared to their baseline. These benefits wereachieved...

Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases

Additional data to be published in an upcoming issue ofAnti-Cancer Drugs VANCOUVER, March 20 /CNW/ - Protox(TM) Therapeutics Inc.(TSX-V:PRX) today announced that two peer-reviewed publicationswill feature Protox's PRX 302. The Journal of the National CancerInstitute ("JNCI") has published the work conducted by Dr. SamDenmeade and his team at Johns Hopkins University in collaboratio...